Multiple myeloma is a plasma cell neoplasm residing in bone marrow. Despite advances in myeloma therapies, novel therapies are required to improve patient outcomes. CD47 is highly expressed on myeloma cells and a potential therapeutic candidate for myeloma therapies. Flow cytometric analysis of patient bone marrow cells revealed that myeloma cells overexpress CD47 when compared with non-myeloma cells in 73% of patients (27/37). CD47 expression protects cells from phagocytosis by transmitting an inhibitory signal to macrophages. Here we show that blocking CD47 with an anti-CD47 monoclonal antibody increased phagocytosis of myeloma cells in vitro. In xenotransplantation models, anti-CD47 antibodies inhibited the growth of RPMI 8226 myeloma cells and led to tumor regression (42/57 mice), implicating the eradication of myeloma-initiating cells. Moreover, anti-CD47 antibodies retarded the growth of patient myeloma cells and alleviated bone resorption in human bone-bearing mice. Irradiation of mice before myeloma cell xenotransplantation abolished the therapeutic efficacy of anti-CD47 antibodies delivered 2 weeks after radiation, and coincided with a reduction of myelomonocytic cells in spleen, bone marrow and liver. These results are consistent with the hypothesis that anti-CD47 blocking antibodies inhibit myeloma growth, in part, by increasing phagocytosis of myeloma cells.
INTRODUCTION
Multiple myeloma is a clonal plasma cell neoplasm that utilizes a bone marrow microenvironment for survival and proliferation. [1] [2] [3] Current myeloma therapies such as hematopoietic cell transplantation and combinatorial chemotherapies are rarely curative and relapse is common. 4 This implies that therapy-resistant myeloma-initiating cells exist and that new therapeutics must be developed to target and eradicate these myeloma-initiating cells.
CD47 is an integrin-associated receptor protein that is expressed on a broad range of cell types, including red blood cells. 5, 6 CD47 interacts with signal regulatory protein-a (SIRPa), thrombospondin (TSP)-1 and -2 to mediate various cellular functions. 7, 8 In particular, CD47 signaling through SIRPa inhibits the phagocytosis of CD47-expressing target cells by SIRPa-expressing macrophages. Anti-CD47 monoclonal antibodies inhibiting the interaction of CD47 and SIRPa promote the phagocytosis of tumor cells by macrophages, and also by monocytes and neutrophils. [9] [10] [11] Cancer cells including acute myelogenous leukemias, 11, 12 lymphomas, 13, 14 and various solid cancers [15] [16] [17] express CD47 at a high level, and can be phagocytosed by macrophages in the presence of blocking antibodies to CD47. [11] [12] [13] [14] [15] [16] [17] In those cases where the tumor-initiating cells (or cancer stem cells) are known, for example, from acute myelogenous leukemias and bladder cancers, the tumor-initiating cells also upregulate CD47 expression, possibly to avoid phagocytosis. Indeed, the enhanced CD47 expression in these cancers has been correlated with poor prognosis. 12, 15, 16 Blocking the CD47-SIRPa interaction with anti-CD47 monoclonal antibodies has proven effective in inducing the phagocytosis of tumor cells in vitro and inhibiting the growth of the various hematological and solid tumors in vivo. 12, 13, 15, 16 A previous microarray analysis indicated that CD47 is among the highly expressed genes by malignant myeloma cells compared with healthy plasma cells. 18 Here, we examined the expression of CD47 on the surface of patient myeloma cells, the therapeutic potential of an anti-CD47 monoclonal antibody (B6H12) in vitro and in xenotransplantation models. The B6H12 mouse anti-CD47 antibodies are of the IgG1 class, and did not induce antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). However, anti-CD47 monoclonal antibodies did induce the phagocytosis of human myeloma cells by macrophages in vitro and significantly inhibited myeloma growth in human fetal bone-free and -bearing xenotransplantation models.
MATERIALS AND METHODS

Preparation of patient bone marrow cells
Clinical bone marrow samples were obtained from newly diagnosed, relapsed or post-treatment patients with multiple myeloma from October 2007 through August 2011, according to protocols approved by the Institutional Review Board of the Stanford University School of Medicine (eprotocol no.: 9718). Mononuclear cells were isolated using Ficoll-Paque (Pharmacia, Uppsala, Sweden).
Human myeloma cell lines and generation of luciferase-expressing RPMI 8226 cell lines, U266, KMS18 and MM1.S, were obtained from Drs Anna Scuto and Richard Jove (City of Hope, Duarte, CA, USA). For in vivo bioluminescence imaging, RPMI 8226 cells were transduced with pCDH-CMV-MCSEF1-puro HIV-based lentiviral vector (Systems Biosciences, Mountain View, CA, USA) encoding eGFP and luciferase as described previously. 16 All human myeloma cell lines were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), Pen/ Strep (Invitrogen), GlutaMax (Invitrogen), sodium pyruvate (Invitrogen), non-essential amino acids (Invitrogen) and b-mercaptoethanol (Sigma, St Louis, MO, USA).
Flow cytometric analysis
The following antibodies were used to stain human bone marrow mononuclear cells: CD138 (B-A38, PE, Beckman Coulter Inc., Fullerton, CA, USA), CD19 (HIB19, AlexaFluor 700 or APC, BD Biosciences, San Jose, CA, USA), CD38 (HIT2, FITC or AlexaFluor, BD Biosciences), CD45 (HI30, PE-cy7, BD Biosciences) and CD47 (B6H12, PE, BD Biosciences). Flow cytometric analysis was performed on a BD FACSAriaII.
Mouse and xenotransplantation models All procedures involving animals were approved by the Stanford University School of Medicine's Administrative Panel on Laboratory Animal Care Committee (protocol no.: 16886). Six-to 10-week-old recombinaseactivating gene 2/common cytokine receptor-g chain-deficient (RAG2 À /gc À ) mice were anesthetized with isofluorane and subcutaneously injected with 2-5 Â 10 5 luciferase-expressing (GFP þ ) RPMI 8226 myeloma cells suspended in phosphate buffered saline (PBS) containing 25% Matrix Matrigel (basement membrane; BD Biosciences). For experiments involving radiation, mice received 400 rad whole-body irradiation using Faxitron Bioptics (Lincolnshire, IL, USA) 12 h before the transplantation of 2000 myeloma cells.
Human bone-bearing RAG2 À /gc À mice were generated as previously reported. [19] [20] [21] Briefly, femurs, tibias and fibulas of 17-to 18-gestational-week-old fetuses (Advanced Bioscience Resources; Alameda, CA, USA) were implanted subcutaneously into 6-8 week-old mice. After 4 weeks, patient bone marrow cells in PBS supplemented with 25% high protein Matrigel (BD Biosciences) were transplanted directly into human bone grafts.
Anti-CD47 antibody treatment of xenograft tumors
Mice transplanted with luciferase-expressing RPMI 8226 were randomized into treatment cohorts after confirming engraftment of myeloma cells with bioluminescent imaging. Antibody treatment consisted of daily intraperitoneal injections of 500 mg of anti-CD47 monoclonal antibody (clone B6H12.2) or mouse polyclonal IgG (Innovative Research, Novi, MI, USA) control in 100 ml of PBS for 4-5 weeks.
Mice transplanted with patient myeloma xenograft or primary myeloma cells were injected intraperitoneally with 500 mg of anti-CD47 monoclonal antibody (B6H12) or PBS daily for 4 weeks after the detection of human antibody in mouse sera.
Phagocytosis assay
Macrophages were derived from bone marrow mononuclear cells of 6-8 week-old RAG2 À /gc À female mice. Bone marrow mononuclear cells were isolated using Ficoll-Paque (Pharmacia) and cultured in RPMI 1640 supplemented with 10% FBS, Pen/Strep (Invitrogen), GlutaMax (Invitrogen), sodium pyruvate (Invitrogen), non-essential amino acids (Invitrogen), b-mercaptoethanol (Sigma) and 20 ng/ml human GM-CSF (Peprotech, Rocky Hill, NJ, USA) for 5-6 days. Adherent macrophages were collected by gentle scraping and plated at a density of 5 Â 10 4 cells per well in a 24-well tissue-culture plate. Human myeloma cells were fluorescently labeled with 2.5 mM carboxyfluorescein succinimidyl ester (CFSE; Invitrogen)) following the manufacturer 0 s instructions. Macrophages were incubated in serumfree medium for 2 h before adding 2 Â 10 5 CFSE-labeled live myeloma cells. Antibodies (10 mg/ml) were added and incubated for 2 h in an incubator maintained at 37 1C. Macrophages were washed at least five times to remove non-phagocytosed myeloma cells, fixed with freshly prepared 4% paraformaldehyde (Sigma) and then imaged using Leica DMI6000 B inverted fluorescence microscope (Leica Microsystems GmbH, Wetzlar, Germany). Composite images were generated from three to five regions from each well, including a bright-field image and fluorescent images. The phagocytic index was calculated as the frequency of phagocytosed CFSE þ myeloma cells per 100 macrophages in the composite images. At least three independent experiments were performed for each cell line and patient samples.
Analysis of anti-CD47 direct cytotoxicity, CDC and antibodydependent cell-mediated cytotoxicity
The cytotoxicity of anti-CD47 (clone B6H12) antibodies was evaluated using XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)-carbonyl)-2H-tetrazolium inner salt; Sigma) assays. Myeloma cells were incubated in RPMI 1640 complete media with or without 10 mg/ml of B6H12. After 24-48 h, XTT and PMS (N-methyl dibenzopyrazine methyl sulfate; Sigma) were added to cells and incubated for 4 h. Colorimetric analysis was performed with Multiskan EX plate reader (Thermo Electron Corporation, Pittsburgh, PA, USA). CDC analysis was performed using two methods. First, we performed XTT assays on myeloma cells cultured with mouse serum (10% intact or heat-inactivated serum) as described above. Second, we performed Calcein AM release assays. Here, myeloma cells were labeled with Calcein AM (Invitrogen) following the manufacturer's instruction and cultured with 10% mouse sera and mouse anti-CD47 antibodies for 4 h. After centrifugation, fluorescence in supernatant was measured with SpectraMax M3 (Molecular Devices, Sunnyvale, CA, USA).
For ADCC assays, we incubated Calcein AM-labeled myeloma cells with mouse peripheral blood cells at the indicated ratio and analyzed as described above.
Bioluminescent imaging
Bioluminescent imaging was performed on an IVIS Spectrum (Caliper Life Science, Hopkington, MA, USA) and quantified using Living Image 4.0 software (Caliper Life Science) as described previously. 16 Mice were imaged 18 min after luciferin injection and total flux (photons/second) values were calculated within a region of interest corresponding to the anatomic region of tumor engraftment when peak radiance was achieved. Mice exhibiting comparable total flux values were then randomized into treatment groups and imaged weekly.
Enzyme-linked immunosorbent assay
Levels of human immunoglobulin kappa or lambda light chains in mouse serum were determined as an indicator of myeloma cell growth using a human kappa or lambda immunoglobulin enzyme-linked immunosorbent assay kits according to the manufacturer's directions (Bethyl Laboratories, Montgomery, TX, USA). Mouse sera were collected every 2-3 weeks to measure the levels of circulating human antibodies.
Histology
Fractionated mouse bone marrow cells were identified morphologically by Wright-Giemsa staining (Sigma-Aldrich, St Louis, MO, USA) of cytospin slide preparations. Slides were evaluated by a minimum of three qualified researchers.
RESULTS
Patient myeloma cells express high levels of CD47
We examined the expression of CD47 on myeloma cells in patients through flow cytometric analysis. Myeloma cells in bone marrow aspirates were identified by the high expression of CD38. 22 Nearly all CD38 high myeloma cells from 37 patient samples expressed CD47. Next, we examined the relative expression level of CD47 on myeloma and non-myeloma cells from the patient bone marrow. We gated bone marrow cells into four subpopulations based on CD38 and CD45 expression and analyzed the mean fluorescence of intensity of CD47. CD38 high and CD38 low/ À CD45 high cells expressed CD47 at higher levels than CD38 low/ À CD45 low cells and CD38
À CD45 À cells of myeloma patients (see Supplementary Figure S1 for representative analyses (Figure 1b) . Lowering the threshold to 1.5-fold, myeloma cells from 73.0% (27/37) of patients had higher expression of CD47 than non-myeloma CD38 low/ À CD45 high cells. CD47 expression was also observed on almost all cells in various myeloma cell lines, including RPMI 8226, NCI H929, MM1s, KMS18 and U266 (Figure 1c) . The universal expression of CD47 on myeloma cells suggests that CD47 may be a potential therapeutic antibody target for myeloma cells, including the myelomainitiating cells enriched within CD38 high cells of multiple myeloma patients. 23, 24 Anti-CD47 antibody, B6H12 promotes the phagocytosis of myeloma cells Blocking CD47 with anti-CD47 monoclonal antibodies has enabled the phagocytosis of leukemia and lymphoma cells. 12, 13, 15 We investigated whether an anti-CD47 monoclonal antibody (B6H12) promotes the phagocytosis of myeloma cells. Macrophages derived from mouse bone marrow cells phagocytosed human myeloma cells at a low frequency when treated with PBS or a control mouse IgG. However, anti-CD47 antibodies significantly increased the phagocytosis of RPMI 8226, NCI H929, KMS18 and MM1.S myeloma cells (Figure 2a) . As shown previously, 12,13,15,25 a non-blocking anti-CD47 antibody, clone 2D3, enabled a minimal increase in phagocytosis (Supplementary Figure S2) . Anti-CD47 antibodies also increased the phagocytosis of patient-derived xenograft myeloma cells (Figure 2b ) and patient bone marrow cells consisting of 95% of myeloma cells (Figure 2c) .
Anti-CD47 antibodies were previously reported to directly initiate cell death upon binding to chronic lymphocytic leukemia cells. 26 We examined whether anti-CD47 antibodies (B6H12) affected the viability of myeloma cells. Neither 10 nor 50 mg/ml of B6H12 affected the viability of RPMI 8226 and NCI H929 myeloma cells after 24-48 h incubation (Supplementary Figure  S3A) . In addition, we did not observe CDC or ADCC initiated by B6H12 at an antibody concentration (10 mg/ml) that promoted phagocytosis of the same myeloma cells (Supplementary Figures  S3B and S3C ). These data indicate that increased phagocytosis of myeloma cells by anti-CD47 antibody (B6H12) does not result as a consequence of cell death caused by direct cytotoxicity, CDC, or ADCC, followed by cell removal.
Anti-CD47 antibodies inhibit the growth of myeloma cells in vivo
We next evaluated whether anti-CD47 antibody treatment inhibits the growth of luciferase-expressing RPMI 8226 cells in RAG2 À /gc À mice. Two weeks after xenotransplantation, we confirmed tumor formation and initiated anti-CD47 antibody therapy (Figure 3a) . In five independent experiments, we observed significantly inhibited tumor growth in mice treated with anti-CD47 antibodies (Figures 3b and c) . In addition to the reduced tumor burden, we observed significant tumor regression in anti-CD47 antibody-treated cohorts compared with mice treated with control mouse IgG (remission rate: 73.7% vs 40.7%) (Figure 3d ). Tumor remission was maintained in anti-CD47 antibody-treated mice 1 week after completion of the 5-week treatment while the regressed tumors in the control group regrew after stopping treatment (remission rate: 71.9% vs 18.6%) (Figure 3d ). These results indicate that anti-CD47 antibody treatment inhibits the growth of RPMI 8226 cells in mice, implicating the eradication of myeloma-initiating cells or myeloma cancer stem cells. Anti-CD47 antibodies inhibited myeloma growth in the presence of a human bone marrow microenvironment The bone marrow microenvironment supports the survival and proliferation of myeloma cells. 2 To determine whether anti-CD47 antibodies also inhibit myeloma growth in the presence of human bone marrow microenvironment, we grafted human fetal bone fragments into immunocompromised mice and directly transplanted patient-derived myeloma cells into the bone grafts. After detecting human immunoglobulin in mouse sera, we treated mice daily with anti-CD47 (B6H12) antibody or PBS for 4 weeks (Figure 4a ). Mice treated with the anti-CD47 antibody produced human immunoglobulin at a lower level than mice in the control (Figure 4b) . Consistent with the myeloma growth in the PBS group, bone grafts in the PBS cohort exhibited significant bone resorption compared with grafts in the anti-CD47 antibodytreated mice (Figure 4c ). The reduction of myeloma growth in the anti-CD47 antibody-treated group was further confirmed by tumor volume measurements (Figure 4d) .
We next examined whether anti-CD47 antibodies inhibit the growth of primary patient myeloma cells in human bone-bearing mice. We transplanted bone marrow cells from four myeloma patients into human bone grafts. After 4 weeks, we treated mice daily with PBS or 500 mg of anti-CD47 antibodies (Figure 5a) . We have previously shown that one can monitor the growth of human myeloma cells by serially analyzing the mouse serum for human immunoglobulin, here myeloma immunoglobulin. 24 Human immunoglobulin was detected in the sera of PBS-treated mice (6/8), although only one of seven anti-CD47 antibody-treated mice produced human antibodies (Figure 5b ). We collected bone marrow cells from human bone grafts 8 weeks after initiation of antibody therapy and examined whether human myeloma cells repopulated in human bone grafts. CD138 þ cells were observed in 4 of 8 mice treated with PBS. In contrast, only 1 of 7 mice treated with anti-CD47 antibodies had detectable human CD138 þ cells (Figure 5c ). These results indicate that blockade of CD47 with targeted monoclonal antibodies inhibits the growth of myeloma cells, even in the context of a human bone marrow microenvironment.
Irradiation abolishes the anti-myeloma effect of anti-CD47 antibody in mice To examine whether the anti-myeloma effect of anti-CD47 antibodies is dependent on cells surviving 400 rad given whole body 2 weeks before the beginning antibody treatment, we sublethally irradiated mice and transplanted luciferase-expressing RPMI 8226 cells; 2 weeks later we treated the mice daily with 500 mg of B6H12 or mouse IgG for 4 weeks (Figure 6a) . Though a small number of tumor cells (2000 cells) were initially transplanted, anti-CD47 antibody therapy did not inhibit tumor growth (Figure 6b ). This implies that the efficacy of anti-CD47 antibody treatment requires irradiation-sensitive effectors, such as progeny of hematopoietic cells. We therefore examined the frequency of myeloid-lineage cells in the bone marrow, spleen and liver of irradiated mice, as RAG2 À /gc À mice lack mature B, T or NK cells. We observed a significant reduction of Gr-1 med Mac-1 þ / À cells in the bone marrow, spleen and liver of irradiated mice compared with those of control mice 10 days after irradiation (Figures 6c  and d) . The morphological analysis of Gr-1 med Mac-1 þ / À cells indicated that these cells enriched for undifferentiated blasts and monocytic cells (Figure 6e ). These cells were further characterized as Ly-6C -CD31 high/ þ cells and macrophage progenitor-enriching
Mac-1 þ cells ( Figure 6f as described by De Bruijn et al. 27 In addition, we observed the reduced Gr-1 low Mac-1 þ macrophages in the spleens of irradiated mice (Figure 6e ). These observations implicate progeny of radiation-sensitive hematopoietic cells in the bone marrow and periphery as critical effectors of the anti-CD47 antibody-mediated therapeutic effect, in addition to the phagocytic activity of resident, radiation-resistant macrophages.
DISCUSSION
CD47 is a multifunctional surface protein expressed in a wide range of cells. In particular, CD47 negatively regulates the phagocytic activity of macrophages. 6,9 CD47 on target cells interacts with SIRPa on macrophages and transmits a 'don't eat me' signal through SH2 domain-containing phosphatases, SHP-1 and -2, and results in the inhibition of target cell phagocytosis. 7, 28, 29 CD47 is expressed at lower levels on bone marrow resident hematopoietic stem cells (HSCs) than on circulating HSCs. However, when bone marrow HSCs were mobilized out of bone marrow, they upregulated CD47. 11 Ide et al. 30 demonstrated that the overexpression of CD47 on donor cells or treatment of recipient mice with soluble CD47 enhanced the engraftment of xenogenic donor cells. This suggests that the overexpression of CD47 may be correlated with higher resistance to phagocytosis by macrophages. Indeed, increased CD47 expression has also been observed on various patient tumor cells. 12, 13, [15] [16] [17] 25 In some instances, CD47 expression levels were highly correlated with a worse prognosis. 12, 13, 15, 16, 25 Here we have shown that in most cases (65%) CD47 expression on patient CD38 high myeloma cells is at least twofold higher than in patient-matched healthy bone marrow cells. Consistent with our observation, Zhan et al. 18 demonstrated that CD47 mRNA expression levels are highly upregulated in myeloma cells compared with healthy plasma cells. In an ongoing parallel study, we found that myeloma-initiating ability is enriched in CD138 þ and/or CD38 high bone marrow cells of multiple myeloma patients. 24 Here we report that nearly 100% of CD38 þ myeloma cells express CD47 at a high level. These results establish CD47 as a potential therapeutic antibody target on myeloma cells, including the critical myeloma-initiating cell subset. Consistent with this hypothesis, anti-CD47 antibody (B6H12) treatment led to the regression of tumors in mice. Although regressed tumors regrew in control IgG-treated mice after stopping treatment, no tumors regrew in mice experiencing remissions following anti-CD47 antibody treatment (Figure 3) , probably caused by the eradication of myeloma-initiating cells.
B6H12 is one of the best-characterized anti-CD47 antibody clones that block the interaction of CD47 and SIRPa. Consistent with previous reports, 12, 13, 15, 25 B6H12 induced the phagocytosis of myeloma cells but a non-blocking anti-CD47 antibody, clone 2D3, showed minimal increase of the phagocytosis (Supplementary Figure S2) . Previously, it was reported that bivalent single-chain antibodies targeting CD47 induced the apoptosis of leukemia, 31 myeloma, 26 monocytes and dendritic cells. 32 However, B6H12 itself did not have cytotoxicity to myeloma cells (Supplementary Figure S3) . Though 10 mg/ml of B6H12 did not induce CDC or ADCC, low concentrations (1-10 ng/ml) of B6H12 induced minimal levels of ADCC, as observed previously. 13 Meanwhile, we found that mouse polyclonal IgG used for control treatment also induced minimal cytotoxicity to myeloma cells (Supplementary Figure S4) .
The anti-myeloma activity of B6H12 appeared to require phagocytic cells or their progenitors such as Gr-1 med Mac-1
monocytic cells, Gr-1 low Mac-1 þ macrophages and a subset of dendritic cells in bone marrow, spleen and liver. The importance of macrophages for anti-CD47 antibody-mediated anti-tumor effects was reported in previous studies wherein immunocompromised mice lacking T cells, B cells and NK cells rapidly eliminated transplanted CD47-deficient hematopoietic cells or human AML cells, but this elimination was blocked following the depletion of macrophages. 12, 33 The bone marrow microenvironment is critical for myeloma cell survival and proliferation. [34] [35] [36] [37] In addition, the bone marrow microenvironment has been reported to protect myeloma cells from chemotherapy. 38, 39 We have shown that patient myeloma cell growth is dependent on human bone marrow microenvironment. 24 The growth of patient myeloma cells was inhibited by anti-CD47 antibodies, even in the presence of a human bone microenvironment. In addition, bone resorption is one of the most severe pathological events in multiple myeloma patients. In our xenotransplantation models, anti-CD47 antibody therapy significantly reduced the human bone resorption. The reduced bone resorption in mice treated with anti-CD47 antibodies indicates that the antibody therapy inhibited the growth of myeloma cells without toxicity to normal human bone marrow cells. Therefore, these results imply that the CD47 therapy may be capable of increasing the quality of life of patients by reducing bone resorption as well as inhibiting myeloma growth.
As a multifunctional protein, CD47 has roles in various biological activities. In addition to acting as a 'don't eat me' signal, Kukreja et al. 40 have suggested a role of CD47 in osteoclastogenesis. CD47 on myeloma cells also interacts with TSP-1 on immature dendritic cells (iDCs) and, it has been reported, induces the differentiation of the iDCs into multinuclear osteoclast-like cells. 40 An anti-TSP-1 antibody blocking the interaction of CD47 and TSP-1 abolished the differentiation of iDCs to osteoclast-like cells. Therefore, blockade of CD47 with anti-CD47 antibodies may abolish the interaction with TSP-1 and inhibit the formation of osteoclast-like cells and reduce bone resorption in patients. Indeed, the reduced bone resorption in mice treated with anti-CD47 antibodies may partially result from reduced osteoclastogenesis.
In this preclinical study, we have shown that CD47 is a promising novel therapeutic target on myeloma cells. Blocking CD47-SIRPa interaction promoted the phagocytosis of myeloma cells and inhibited the growth of ectopically growing myeloma cells and patient primary myeloma cells growing in human bone marrow microenvironment. To improve the anti-myeloma effect, therapies that combine other anti-myeloma antibodies or other agents with anti-CD47 antibodies are currently under investigation. 
